Kestra Advisory Services’s Biolase, Inc. BIOL Stock Holding History

Kestra Advisory Services’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5	Closed	-$5K	–	2254
2022 Q1	$5K	Buy	+5	New	+$4.61K	﹤0.01%	1997

Other funds holding BIOL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Kestra Advisory Services's BIOL Position: Q2 2022 in Review

Kestra Advisory Services sold out of Biolase, Inc. (BIOL) in Q2 2022, closing a stake of 5 shares — an estimated $5K sold.

Kestra Advisory Services first reported a position in BIOL in Q1 2022 and held it in 1 quarter. The position peaked at $5K in Q1 2022. 16 funds tracked by Wall St. Rank hold BIOL as of Q2 2022.

Kestra Advisory Services reported no remaining Biolase, Inc. position as of Q2 2022 after selling out during the quarter.
Kestra Advisory Services sold 5 Biolase, Inc. shares in Q2 2022, an estimated $5K.
Kestra Advisory Services first reported a position in Biolase, Inc. in Q1 2022 and held it in 1 quarter.
Kestra Advisory Services's Biolase, Inc. position peaked at $5K in Q1 2022.
16 funds tracked by Wall St. Rank held Biolase, Inc. as of Q2 2022.

Based on Kestra Advisory Services's 13F filing for Q2 2022, filed 12 Aug 2022.